In a research report published Wednesday, Roth Capital analyst Chris Lewis reiterated a Neutral rating on shares of EXACT Sciences Corporation (NASDAQ:EXAS), with a $7.00 price target, on the back of an apparent leaked JAMA article unveiling the final USPSTF colorectal cancer screening guidelines. EXAS is currently trading at $10.06, up $0.67 or 7.19%.
Lewis noted, “Assuming the article is indeed the USPSTF final recommendation and is published as is presented in the link above, we would view this as a positive development for EXAS as it would likely allow the company to secure more widespread commercial reimbursement coverage in a timelier manner. Further, this could accelerate commercial adoption and utilization, in our view. That said, we don’t think it’s a given that commercial insurers will view the updated guidelines as a mandate to cover and pay for all screening strategies presented in the guidelines, including Cologuard, given there are not specific A/B grade recommendations in the updated recommendation.”
“We acknowledge yesterday’s leaked article has not been published and therefore may not be final yet. As such, questions remain. Given the lack of clarity, we will revisit our rating and target price on EXAS if/when the USPSTF issues its final recommendation, which appears more imminent now. Until then, we expect shares will remain volatile and likely trend higher on the potential for the positive USPSTF development to officially materialize,” the analyst concluded.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Chris Lewis has a yearly average return of 1.1% and a 47% success rate. Lewis has an -56% average return when recommending EXAS, and is ranked #1488 out of 3974 analysts.
Out of the 12 analysts polled by TipRanks (in the past 12 months), 8 rate Exact Sciences stock a Hold, while 4 rate the stock a Buy. With a downside potential of 12%, the stock’s consensus target price stands at $8.65.